BIOMAT Database Logo BIOMAT Database Logo

Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. 2018

Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Hasselt University, Faculty of Medicine and Life Sciences, Martelarenlaan 42, B-3500 Hasselt, Belgium.

To predict the outcome of patients with non-small cell lung cancer (NSCLC) the currently used prognostic system (TNM) is not accurate enough. The prognostic significance of the SUVmax measured by PET remains controversial. This study aims to evaluate the prognostic value in overall survival and progression free survival of SUVmax, the total lesion glycolysis (TLG) and the mean metabolic active volume (MATV) in NSCLC. We retrospectively reviewed 105 patients (72 males, 33 females) with a new diagnosis of NSCLC (TNM stage I: 27.6%, II: 10.5%, III: 40.9% and IV: 21.0%) who underwent scanning with a PET/CT. For VOI definition a semi-automatic delineation tool was used. On PET images SUVmax, SUVmean and MATV of the primary tumor and the whole tumor burden were measured. TLG and MATV were measured by using a threshold of 50% of SUVmax. OS and PFS are found to be higher in patients with low-SUVTmax and low-TLGT values. OS and PFS were significantly higher for low-SUVWTBmax, low-MATVWTB and low-TLGWTB values of the whole-tumor burden. Multivariate analysis of the whole-tumor burden revealed that the most important prognostic factors for OS are high MATVWTB and TLGWTB values, increasing stage and male gender. TLGWTB and stage are also independent prognosticators in PFS. Only whole-body TLG is of prognostic value in NSCLC for both OS and PFS. Stratification of patients by TLGWTB might complement outcome prediction but the TNM stage remains the most important determinant of prognosis. In order to predict the outcome of patients with non-small cell lung cancer (NSCLC) the currently used prognostic system (TNM) is not accurate enough. The prognostic significance of the standard uptake value (SUV) measured by PET remains controversial. This study aims to evaluate the prognostic value in overall survival (OS) and progression free survival (PFS) of the standard uptake value (SUV), the total lesion glycolysis (TLG) and the mean metabolic active volume (MATV) in NSCLC. The study reveals that TLG of the whole-tumor burden is an independent prognostic factor for OS and PFS in patients with NSCLC.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D005260 Female Females
D006019 Glycolysis A metabolic process that converts GLUCOSE into two molecules of PYRUVIC ACID through a series of enzymatic reactions. Energy generated by this process is conserved in two molecules of ATP. Glycolysis is the universal catabolic pathway for glucose, free glucose, or glucose derived from complex CARBOHYDRATES, such as GLYCOGEN and STARCH. Embden-Meyerhof Pathway,Embden-Meyerhof-Parnas Pathway,Embden Meyerhof Parnas Pathway,Embden Meyerhof Pathway,Embden-Meyerhof Pathways,Pathway, Embden-Meyerhof,Pathway, Embden-Meyerhof-Parnas,Pathways, Embden-Meyerhof
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077982 Progression-Free Survival Length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but the disease does not get worse. Event-Free Survival,Event Free Survival,Progression Free Survival,Survival, Event-Free,Survival, Progression-Free

Related Publications

Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Prognostic value of metabolic tumor volume and total lesion glycolysis in breast cancer: a meta-analysis.
August 2020, Nuclear medicine communications,
Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.
June 2012, Annals of surgical oncology,
Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
October 2013, Nuclear medicine communications,
Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer.
November 2015, Oncology letters,
Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
August 2012, Radiology,
Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Prognostic value of metabolic tumor volume and total lesion glycolysis assessed by 18F-FDG PET/CT in endometrial cancer.
November 2019, Nuclear medicine communications,
Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Prognostic value of metabolic tumor volume and total lesion glycolysis in esophageal carcinoma patients treated with definitive chemoradiotherapy.
June 2018, Nuclear medicine communications,
Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
January 2019, PloS one,
Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis.
June 2014, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Karolien Vanhove, and Liesbet Mesotten, and Micheline Heylen, and Ruben Derwael, and Evelyne Louis, and Peter Adriaensens, and Michiel Thomeer, and Ronald Boellaard
Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.
January 2013, European journal of nuclear medicine and molecular imaging,
Copied contents to your clipboard!